GlassScriptPhysician profile
Mary K Simpson
NPI 1023181864
$8,027.85
in general payments reported to CMS, 2019-2025
37 companies · $2,378 in 2025
The $2,378 reported for 2025 was more than what 96% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $51.87 · 2022: $1,212 · 2023: $1,872 · 2024: $2,514 · 2025: $2,378.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,764.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,763.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,561.77 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,200.09 | 2022-2025 | Airsupra, Breztri, Farxiga |
| Abbvie INC. | $1,167.58 | 2022-2025 | |
| Pfizer INC. | $966.86 | 2021-2025 | |
| Lilly USA, LLC | $390.18 | 2022-2025 | Mounjaro, Zepbound |
| Amgen INC. | $300.74 | 2022-2025 | Otezla, Repatha, Otezla |
| Bayer Healthcare Pharmaceuticals INC. | $258.85 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $247.56 | 2022-2025 | Jardiance, Stiolto Respimat |
| Glaxosmithkline, LLC. | $192.89 | 2022-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbott Laboratories | $192.48 | 2022-2025 | Freestyle Libre 3 |
| Baxter Healthcare | $155.74 | 2024 | |
| Phathom Pharmaceuticals, INC. | $140.94 | 2024-2025 | Voquezna |
| Biohaven Pharmaceutical Holding Company LTD. | $137.42 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $114.19 | 2023-2025 | Xifaxan, Trulance |
| Sanofi-Aventis U.S. LLC | $101.17 | 2022-2023 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $88.11 | 2022-2024 | Veozah |
| Exact Sciences Corporation | $81.98 | 2023-2025 | Cologuard Collection Kit |
| Axsome Therapeutics, INC. | $69.63 | 2024-2025 | Auvelity, Symbravo |
| Ardelyx, INC. | $66.71 | 2025 | Ibsrela |
| Daiichi Sankyo INC. | $62.95 | 2024-2025 | Injectafer |
| Supernus Pharmaceuticals, INC. | $60.10 | 2022-2025 | Qelbree, Xyosted |
| Shield Therapeutics INC | $55.01 | 2024 | |
| Antares Pharma, INC. | $51.02 | 2022-2025 | Xyosted |
| Merck Sharp & Dohme LLC | $44.45 | 2022-2025 | Pneumovax 23, Gardasil 9, Vaxneuvance |
| Xeris Pharmaceuticals, INC. | $36.21 | 2024-2025 | Gvoke Hypopen |
| Nestle Healthcare Nutrition INC. | $36.12 | 2022-2023 | |
| Aimmune Therapeutics, INC. | $31.75 | 2024-2025 | Zenpep |
| Takeda Pharmaceuticals U.S.A., INC. | $28.27 | 2022 | |
| Averitas Pharma INC. | $27.09 | 2025 | Qutenza |
| Sumitomo Pharma America, INC. | $26.48 | 2024 | Gemtesa |
| Halozyme INC | $22.92 | 2023 | |
| Corium, LLC | $21.76 | 2025 | Azstarys |
| Genentech USA, INC. | $18.72 | 2024 | Xofluza |
| Millicent US INC | $18.56 | 2025 | Femlyv, Intrarosa |
| Esperion Therapeutics, INC. | $17.77 | 2022 | |
| Currax Pharmaceuticals LLC | $17.37 | 2022 | |
| Ironwood Pharmaceuticals, INC | $16.41 | 2023 | Linzess |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Simpson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.